Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; none of the 31 sources its claims cite is checked for support yet.
Abstract
Advances in mRNA technology have enabled mRNA-based therapies to enter a new era of medicine. Such therapies benefit from a single, standardized in vitro transcription (IVT) manufacturing process applicable to a wide range of targets. This process includes several downstream purification steps, which aim to eliminate impurities that potentially affect safety and efficacy. However, it is not fully understood which impurities are the most critical; hence, some efforts are still needed to establish the correlation between RNA impurities and their role in limiting therapeutic efficacy. To study this relationship, we produced in vitro-transcribed mRNAs using several bacteriophage T7 RNA polymerases, including one wild-type and four engineered variants. Important attributes of the mRNA such as integrity, purity, and functional activity were then measured using advanced physicochemical and cellular assays. For impurities including abortive transcripts, mRNAs containing partial poly(A) tails, and double-stranded (ds)RNA byproducts, structure-function relationships have been established by tracking cellular responses (i.e., protein expression, reactogenicity) in multiple cell models. By varying the T7 RNA polymerase, different levels of sense-antisense dsRNA byproducts were measured by mass photometry, contributing directly to immunological reactogenicity in bone marrow-derived dendritic cells. T7 RNA polymerase differences with regard to short (<20 nucleotides) 3'-loopback dsRNA byproducts were also further investigated using native mass spectrometry by precisely resolving these impurities at the nucleotide level. Overall, this study highlights the importance of developing sensitive and advanced analytical methods to characterize IVT mRNA impurities and understand their interaction with cellular machinery in order to ensure quality control of RNA-based therapies.
Overview
CoChat Summary
TL;DR
Using five T7 RNA polymerases (one wild-type and four engineered mutants), this study links IVT mRNA impurities—abortive transcripts, partial poly(A)/3′-heterogeneity, and dsRNA byproducts—to protein expression and innate immune activation in human and mouse cell models. Engineered T7 RNAPs reduced abortive transcripts and dsRNA/HMW species, improving translation and lowering reactogenicity, while mass photometry and native MS resolved distinct impurity classes.
Key findings
- T7 RNAP choice changed mRNA purity: abortive-transcript prepeak levels by CGE and IP-RP HPLC were highest for T_WT (12.9 and 11.7%) and lowest for T_E3 (3.6 and 1.5%); postpeak 3′-loopback dsRNA was similar across assays at close to 3.5%.
- Protein expression correlated with purity: Pearson r values were 0.82 for main peak and 0.84 for prepeak. In CD8+ T cells at day 1, T_WT mRNA gave the lowest zsGreen expression (35–65%) versus mutants (80–95%); T_E2 had the lowest HMW level (4%) and highest expression (≈92% at day 1), a 2-fold improvement over T_WT. eGFP_160 poly(A) gave 60% positive cells at day 1 versus 52% and 44% for 110 and 90 adenosine residues; IP-RP purification improved purity by 25% and expression to >95% at day 1, 60% at day 5, and 15% at day 8.
- Reactogenicity tracked dsRNA/HMW impurities: T_WT showed the highest dsRNA by ELISA (≈13–30 AU) and the highest BMDC activation, T_E1 and T_E2 were least activating, and T_E3/T_E4 were intermediate; HMW levels by MP/mCE positively correlated with BMDC activation. ELISA did not detect dsRNA for m1Ψ-modified mRNAs except T_WT, while MP showed similar levels to unmodified mRNAs.
- Native MS resolved short impurities: for mRNA_T (theoretical mass 120.5 kDa), T_WT showed n+1 and n+2 ratios of 0.60 and 0.15, while T_E1 was below 0.05 for both; 3′-loopback species differed by 2517 and 5074 Da, corresponding to 8 and 16 nucleotides, and represented 30–50% of total mRNA species for T_WT, T_E2, and T_E4 but below 5% for T_E1 and T_E3.
Methods
- IVT reactions used five T7 RNAPs (one WT, four mutants) with PCR or linearized DNA templates encoding zsGreen, mScarlet, eGFP constructs with 90/110/160-adenosine poly(A) tails, and a smaller mRNA_T construct.
- Cellular models included human monocyte-derived dendritic cells, human CD8+ T cells, and mouse FLT3L-derived bone marrow-derived dendritic cells; DCs received mRNA-LPX complexes (DOTMA/DOPE at a 1.3:2 charge ratio), and moDCs received zsGreen mRNA by electroporation.
- Analytics included IP-RP HPLC/UV, CGE-LIF, mass photometry, native mass spectrometry, dsRNA ELISA, mCE, flow cytometry, and Luminex; purity/impurity measures were correlated with protein expression and immune activation, including Pearson correlation.
Limitations
- Stated in the paper: the exact mechanisms behind 3′-heterogeneity and 3′-loopback transcription remain unknown; native MS of large mRNAs is limited by long size, adduct formation, and inherent heterogeneity, with insufficient resolution for zsGreen intact mass and a need for further instrument development.
- Stated in the paper: the J2 dsRNA ELISA may be insufficiently specific or sensitive for m1Ψ-modified mRNA, or m1Ψ may alter mRNA conformation; CGE cannot distinguish short 3′-loopback dsRNA, mCE showed limited resolution, and the J2 antibody cannot bind dsRNA <40 bp.
- Evident from the text: functional comparisons used small samples in places (e.g., N = 2 donors for some expression data; N = 6 in 3 experiments for BMDC cytokine data), and the paper notes mouse-to-mouse variability, species-related differences between human and mouse expression hierarchies, and possible sequence-specific effects between zsGreen and mScarlet.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
0 Valid · 0 Not valid · 20 Not checked · 86 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CGE and IP-RP HPLC data displayed different prepeak profiles for each enzyme indicating varying levels of abortive transcripts.”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > T7 RNAP Affects mRNA Purity Profile, Resulting in a Direct Impact on Protein Expression
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, the data confirm that the nature of T7 RNAP affects the integrity of IVT mRNA by generating varying levels of abortive transcripts.”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > T7 RNAP Affects mRNA Purity Profile, Resulting in a Direct Impact on Protein Expression
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, mRNAs derived from T_WT induced the highest levels of BMDC activation for the zsGreen and mScarlet constructs.”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > Innate Immune Response is Activated by dsRNA Byproducts
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These trends match the MP measurements (Figure 2b), demonstrating the ability of the technology to detect sense–antisense dsRNA byproducts.”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > Innate Immune Response is Activated by dsRNA Byproducts
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This demonstrated a positive correlation between the poly(A) tail length and protein expression (see Figure 1f).”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > T7 RNAP Affects mRNA Purity Profile, Resulting in a Direct Impact on Protein Expression
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
57 more claims
Create a free account to see all 106 claims and to verify the 30 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 12
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > Protein Translation is Impacted by Noncovalent High-Molecular-Weight (HMW) Species
“it is lowest for T_E2 (5.0%)”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > Protein Translation is Impacted by Noncovalent High-Molecular-Weight (HMW) Species
“mRNA produced by the T_E2 mutant was associated with the lowest amount of HMWs (4%)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > Protein Translation is Impacted by Noncovalent High-Molecular-Weight (HMW) Species
“it is lowest for T_E2 (5.0%)”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > Protein Translation is Impacted by Noncovalent High-Molecular-Weight (HMW) Species
“T_E1, T_E3, and T_E4 (5.1, 4.5, and 6.0%, respectively)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > T7 RNAP Affects mRNA Purity Profile, Resulting in a Direct Impact on Protein Expression
“T_E2 (12.1 and 10.3%) >”
§ Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses > Results > T7 RNAP Affects mRNA Purity Profile, Resulting in a Direct Impact on Protein Expression
“T_E1 (12.6 and 5.5%)”
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates
Milligan, J. F., Groebe, D. R., Witherell, G. W., & Uhlenbeck, O. C. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.21.8783 · Cited by 2,136
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Marty, M. T., Baldwin, A. J., Marklund, E. G., Hochberg, G. K. A., Benesch, J. L. P., & Robinson, C. V. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00140 · Cited by 1,000
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
High-Resolution Native Mass Spectrometry
Tamara, S., den Boer, M. A., & Heck, A. J. R. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00212 · Cited by 511
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
Double-Stranded RNA Sensors and Modulators in Innate Immunity
Hur, S. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041356 · Cited by 420
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher Eukaryotes
Kumar, M., & Carmichael, G. G. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1415-1434.1998 · Cited by 320
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina-Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 279
Vaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 241
An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts
Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J., & Rabideau, A. E. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01525-6 · Cited by 235
An origin of the immunogenicity of in vitro transcribed RNA
Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218
Ribonuclease III mechanisms of double‐stranded RNA cleavage
Nicholson, A. W. (2014) · WIREs RNA · doi:10.1002/wrna.1195 · Cited by 214
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Oude Blenke, E., Örnskov, E., Schöneich, C., Nilsson, G. A., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 206
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180
Synthesis of low immunogenicity RNA with high-temperature in vitro transcription
Wu, M. Z., Asahara, H., Tzertzinis, G., & Roy, B. (2020) · RNA · doi:10.1261/rna.073858.119 · Cited by 136
Immunogenicity of In Vitro-Transcribed RNA
Mu, X., & Hur, S. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00521 · Cited by 134
Superior 5' homogeneity of RNA from ATP-initiated transcription under the T7 2.5 promoter
Coleman, T. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh007 · Cited by 121
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 108
Freund, E. C., Lock, J. Y., Oh, J., Maculins, T., Delamarre, L., Bohlen, C. J., Haley, B., & Murthy, A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191692 · Cited by 106
Self-citationBaumann, P., & Hubbuch, J. J. (2016) · Engineering in Life Sciences · doi:10.1002/elsc.201600033 · Cited by 92
Camperi, J., Lippold, S., Ayalew, L., Roper, B., Shao, S., Freund, E. C., Nissenbaum, A., Galan, C., Cao, Q., Yang, F., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05539 · Cited by 80
Self-citationDouble-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA
Piao, X., Yadav, V., Wang, E., Chang, W., Tau, L., Lindenmuth, B. E., & Wang, S. X. (2022) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2022.08.001 · Cited by 79
RNA synthesis: strategies for the use of bacteriophage RNA polymerases
Krupp, G. (1988) · Gene · doi:10.1016/0378-1119(88)90129-1 · Cited by 67
Guidelines for mouse and human DC generation
Lutz, M. B., Ali, S., Audiger, C., Autenrieth, S. E., Berod, L., Bigley, V., Cyran, L., Dalod, M., Dörrie, J., Dudziak, D., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202249816 · Cited by 63
Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals
Fekete, S., Doneanu, C. E., Addepalli, B., Gaye, M. M., Nguyen, J. M., Alden, B. A., Birdsall, R. E., Han, D., Isaac, G., & Lauber, M. A. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115174 · Cited by 59
Miller, M. G., Alvizo, O., Baskerville, S., Chintala, A., Chng, C., Dassie, J. P., Dorigatti, J. D., Huisman, G. W., Jenne, S., Kadam, S., et al. (2024) · Faraday Discussions · doi:10.1039/d4fd00023d · Cited by 45
Characterization of mRNA therapeutics
Guimaraes, G. J., Kim, J., & Bartlett, M. G. (2024) · Mass Spectrometry Reviews · doi:10.1002/mas.21856 · Cited by 44
Camperi, J., Moshref, M., Dai, L., & Lee, H. Y. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04795 · Cited by 32
Self-citationOptimizing Messenger RNA Analysis Using Ultra-Wide Pore Size Exclusion Chromatography Columns
D’Atri, V., Lardeux, H., Goyon, A., Imiołek, M., Fekete, S., Lauber, M. A., Zhang, K., & Guillarme, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116254 · Cited by 27
Luo, D., Wu, Z., Wang, D., Zhang, J., Shao, F., Wang, S., Cestellos-Blanco, S., Xu, D., & Cao, Y. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.005 · Cited by 26
Aramburu, J., Navas‐Castillo, J., Moreno, P., & Cambra, M. (1991) · Journal of Virological Methods · doi:10.1016/0166-0934(91)90002-h · Cited by 21
Piao, X., Tang, Y., Li, X., Zhang, W., Yang, W., Xu, X., Wang, W., Jiang, J., Xu, J., Hu, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102223 · Cited by 19
Effective recognition of double-stranded RNA does not require activation of cellular inflammation
Drążkowska, K., Cieslicka, J., Kitowicz, M., Pastucha, A., Markiewicz, Ł., Szymanek, W., Goryca, K., Kowalczyk, T., Cysewski, D., Bausch, A. R., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads6498 · Cited by 16
Miller, M., Alvizo, O., Chng, C., Jenne, S., Mayo, M., Mukherjee, A., Sundseth, S., Chintala, A., Penfield, J., Riggins, J., et al. (2022) · doi:10.1101/2022.09.01.506264 · Cited by 11
An immuno‐northern technique to measure the size of dsRNA byproducts in in vitro transcribed RNA
Clark, N. E., Schraut, M. R., Winters, R. A., Kearns, K., & Scanlon, T. C. (2024) · Electrophoresis · doi:10.1002/elps.202400036 · Cited by 10
Combes, F., Bui, T.-H., Pettersson, F. J., & Hak, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2363029 · Cited by 3
Detection of dsRNA with Fluorescence In Situ Hybridization (FISH)
Zhou, W., Huang, J., Yang, X., & Zhang, X. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3702-9_6 · Cited by 2
Nucleic Acid Recognition in Dendritic Cells
Heiseke, A., Eisenächer, K., & Krug, A. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-4939-0882-0_6 · Cited by 1
Effective recognition of double-stranded RNA does not require activation of cellular inflammation
Drazkowska, K., Cieslicka, J., Pastucha, A., Markiewicz, L., Goryca, K., Kowalczyk, T., Cysewski, D., Bausch, A., & Sikorski, P. J. (2024) · doi:10.1101/2024.05.24.595663 · Cited by 1
Cited by
Current Analytical Strategies for mRNA-Based Therapeutics
Camperi, J., Chatla, K., Freund, E. C., Galan, C., Lippold, S., & Guilbaud, A. (2025) · Molecules · doi:10.3390/molecules30071629 · Cited by 51
Self-citationmRNA vaccines: immunogenicity and quality characteristics
Quan, Y., Yang, H., Li, W., & Li, L. X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03800-5 · Cited by 33
Broset, E., Lampaya, V., Larraga, A., Navarro, V., López-Gavín, A., de Miguel, D., Peña, Á., Martínez-Oliván, J., & Casabona, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115138 · Cited by 22
Grudzinska‐Goebel, J., Braun, M., Chen, L., Gupta, S., Lohmann, S., Morais, P., Niu, T., Tarcsa, E., Tourdot, S., Youssef, A. S., et al. (2025) · Nucleic Acid Therapeutics · doi:10.1177/21593337251387423 · Cited by 21
Removal of dsRNA byproducts using affinity chromatography
Clark, N. E., Kozarski, M., Asci, S. D., den Heuvel, J. V., Schraut, M. R., Winters, R. A., Kearns, K., Scanlon, T. C., & Dillen, S. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102549 · Cited by 21
Metadata
- Authors
- Camperi, J., Roper, B., Freund, E., Leylek, R., Nissenbaum, A., Galan, C., Caothien, R., Hu, Z., Ko, P., Lee, A., Chatla, K., Ayalew, L., Yang, F., Lippold, S., & Guilbaud, A.
- Affiliations
- Genentech (US)
- Corresponding author
- Camperi, Julien
- Guilbaud, Axel
- ORCID
- Venue
- Analytical Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-10-24
- Volume
- 96
- Issue
- 44
- Pages
- 17789-17799
- ISSN
- 0003-2700 (ISSN-L)
- 1520-6882
- PMC
- PMC11542617
- OpenAlex
- W4403737274
- Cited by
- 22
- References
- 46
- Citations by year
- 2026: 12 · 2025: 10
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Analytical Chemistry (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
- Keywords
- in vitro transcribed mRNA, mRNA therapeutics, mRNA quality control, structure-function relationship, native mass spectrometry, mass photometry
- MeSH terms
- Animals, Humans, DNA-Directed RNA Polymerases, RNA, Messenger, Transcription, Genetic, Viral Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.